MacroGenics (MGNX) Competitors $3.39 +0.05 (+1.50%) (As of 09:46 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MGNX vs. AVXL, IMNM, KURA, KROS, TYRA, ERAS, CRON, EOLS, DNTH, and RAPPShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Anavex Life Sciences (AVXL), Immunome (IMNM), Kura Oncology (KURA), Keros Therapeutics (KROS), Tyra Biosciences (TYRA), Erasca (ERAS), Cronos Group (CRON), Evolus (EOLS), Dianthus Therapeutics (DNTH), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Anavex Life Sciences Immunome Kura Oncology Keros Therapeutics Tyra Biosciences Erasca Cronos Group Evolus Dianthus Therapeutics Rapport Therapeutics Anavex Life Sciences (NASDAQ:AVXL) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts prefer AVXL or MGNX? Anavex Life Sciences presently has a consensus target price of $43.00, indicating a potential upside of 366.88%. MacroGenics has a consensus target price of $7.63, indicating a potential upside of 128.29%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Which has higher valuation and earnings, AVXL or MGNX? MacroGenics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$47.51M-$0.50-18.42MacroGenics$139.77M1.50-$9.06M-$1.58-2.11 Does the MarketBeat Community favor AVXL or MGNX? Anavex Life Sciences received 5 more outperform votes than MacroGenics when rated by MarketBeat users. Likewise, 74.44% of users gave Anavex Life Sciences an outperform vote while only 62.28% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformAnavex Life SciencesOutperform Votes43174.44% Underperform Votes14825.56% MacroGenicsOutperform Votes42662.28% Underperform Votes25837.72% Which has more risk & volatility, AVXL or MGNX? Anavex Life Sciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Do institutionals and insiders believe in AVXL or MGNX? 31.5% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by insiders. Comparatively, 11.3% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer AVXL or MGNX? In the previous week, Anavex Life Sciences had 2 more articles in the media than MacroGenics. MarketBeat recorded 4 mentions for Anavex Life Sciences and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.34 beat Anavex Life Sciences' score of 0.94 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AVXL or MGNX more profitable? Anavex Life Sciences has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Anavex Life Sciences' return on equity of -30.64% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -30.64% -28.23% MacroGenics -69.07%-89.42%-38.57% SummaryAnavex Life Sciences beats MacroGenics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$209.63M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-2.1110.75135.1817.53Price / Sales1.50287.861,235.42140.39Price / CashN/A56.6540.6537.95Price / Book1.365.394.884.92Net Income-$9.06M$152.04M$118.97M$225.78M7 Day Performance-2.05%-4.32%16.19%-1.58%1 Month Performance-4.84%2.80%16.02%6.67%1 Year Performance-61.52%17.30%34.95%22.48% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics3.8078 of 5 stars$3.39+1.5%$7.63+124.9%-63.9%$212.77M$139.77M-2.15430AVXLAnavex Life Sciences3.4502 of 5 stars$9.27+9.6%$43.00+363.9%+4.2%$786.10MN/A-18.5440IMNMImmunome2.802 of 5 stars$12.47-0.9%$28.83+131.2%+59.4%$778.34M$10.13M-1.5540Short Interest ↓Positive NewsKURAKura Oncology4.6093 of 5 stars$9.94+3.2%$29.38+195.5%-20.8%$772.93MN/A-4.08142KROSKeros Therapeutics3.0812 of 5 stars$18.80-0.2%$81.33+332.6%-44.6%$761.53M$651,000.00-3.61100Analyst DowngradeHigh Trading VolumeTYRATyra Biosciences2.4681 of 5 stars$14.97+0.2%$31.00+107.1%+12.7%$757.48MN/A-9.2820Gap DownERASErasca2.6376 of 5 stars$2.60+1.6%$5.90+126.9%+40.6%$735.09MN/A-3.08126Positive NewsGap UpCRONCronos Group2.3265 of 5 stars$1.92-0.5%$3.00+56.3%+1.0%$734.02M$87.24M-15.19356Short Interest ↓News CoveragePositive NewsEOLSEvolus3.9308 of 5 stars$11.53+0.2%$23.00+99.5%+18.5%$730.08M$202.09M-12.73170DNTHDianthus Therapeutics1.666 of 5 stars$24.33+2.2%$46.43+90.8%+235.7%$720.17M$2.83M-9.5280Positive NewsRAPPRapport Therapeutics1.8417 of 5 stars$19.36+3.1%$35.00+80.8%N/A$708.19MN/A0.00N/APositive News Related Companies and Tools Related Companies Anavex Life Sciences Alternatives Immunome Alternatives Kura Oncology Alternatives Keros Therapeutics Alternatives Tyra Biosciences Alternatives Erasca Alternatives Cronos Group Alternatives Evolus Alternatives Dianthus Therapeutics Alternatives Rapport Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGNX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGNX Stock Alerts